Biora Therapeutics

Representation of the creditors’ committee in the chapter 11 cases of Biora Therapeutics, then publicly traded with 4.5 million outstanding common stock shares, and its debtor affiliates filed in the District of Delaware. The debtors were a preclinical stage medical technology device company primarily focused on the oral delivery of biotherapeutics including smart pills designed to target drug delivery to the GI tract orally. With the firm’s assistance and counsel, the creditors’ committee was successful in negotiating a settlement with the debtors and their lenders in connection with the debtors’ sale of substantially all of their assets and the establishment of a trust for the benefit of trade creditors and other unsecured creditors.